The authors concluded that when cost and time are a consideration and the added value of Oncotype DX testing is in question, it may be reasonable to assume the results of this test in two specific subsets of breast cancers: grade 1, high progesterone receptor, low Ki67 cancers (low recurrence score), and grade 3, low progesterone receptor, high Ki67 cancers (high recurrence score).